Evidence map›Paper›PMID 31540362›Full record

ReviewMolecules (Basel, Switzerland)2019

Yeast Models for Amyloids and Prions: Environmental Modulation and Drug Discovery.

Tatiana A Chernova, Yury O Chernoff, Keith D Wilkinson

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. International journal of molecular sciences · 2023
    Review
  2. The Aβ42 Peptide and IAPP Physically Interact in a Yeast-Based Assay.International journal of molecular sciences · 2023
    Article
  3. Review
  4. Yeast as a Model to Find New Drugs and Drug Targets forInternational journal of molecular sciences · 2022
    Review
  5. The HMGB ProteinBiomolecules · 2021
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Tatiana A ChernovaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. tcherno@emory.edu.ORCID 0000-0003-1966-0159
Yury O ChernoffSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA. yury.chernoff@biology.gatech.edu.
Keith D WilkinsonDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. genekdw@emory.edu.
Emory University · USGeorgia Institute of Technology · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WALKER, LARY C · 2005 to 2019
$25.7M
National Science Foundation MCB1817976NIH HHS GM093294NIH HHS P50AG025688NIH HHS P51 OD011132
6 · The paper itself

Abstract

Amyloids are self-perpetuating protein aggregates causing neurodegenerative diseases in mammals. Prions are transmissible protein isoforms (usually of amyloid nature). Prion features were recently reported for various proteins involved in amyloid and neural inclusion disorders. Heritable yeast prions share molecular properties (and in the case of polyglutamines, amino acid composition) with human disease-related amyloids. Fundamental protein quality control pathways, including chaperones, the ubiquitin proteasome system and autophagy are highly conserved between yeast and human cells. Crucial cellular proteins and conditions influencing amyloids and prions were uncovered in the yeast model. The treatments available for neurodegenerative amyloid-associated diseases are few and their efficiency is limited. Yeast models of amyloid-related neurodegenerative diseases have become powerful tools for high-throughput screening for chemical compounds and FDA-approved drugs that reduce aggregation and toxicity of amyloids. Although some environmental agents have been linked to certain amyloid diseases, the molecular basis of their action remains unclear. Environmental stresses trigger amyloid formation and loss, acting either via influencing intracellular concentrations of the amyloidogenic proteins or via heterologous inducers of prions. Studies of environmental and physiological regulation of yeast prions open new possibilities for pharmacological intervention and/or prophylactic procedures aiming on common cellular systems rather than the properties of specific amyloids.

Indexed as

Models, BiologicalAmyloidAnimalsFungal ProteinsHumansNeurodegenerative DiseasesYeastsAmyloidFungal Proteinsamyloidchaperonedrug discoveryenvironmental factorsheat shockneurodegenerative diseaseprionubiquitin

Identifiers

PMID31540362
PMCPMC6767215
OpenAlexW2973824124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.